Endeavor BioMedicines, a clinical-stage biotechnology company targeting the core drivers of terminal diseases including oncology and fibrosis, and xCures, a company that aims to improve cancer outcomes and accelerate cancer research using artificial intelligence, today announced a partnership that gives patients enrolling in Endeavor's clinical trials access to the xCures platform to find the best available treatment options suited to their individual tumor profile. The partnership helps identify patients whose cancers harbor the PTCH1 mutation and may be eligible for Endeavor’s clinical trial. The xCures platform also enables patients to find more suitable treatment options if they are ineligible.
top of page
Search
Recent Posts
See AllBy: Steven Loeb Venture capital used to be a cottage industry, with very few investing in tomorrow's products and services. Oh, how times...
Matterworks, Inc., developers of the world's most powerful metabolomics platform, which accelerates the discovery, development, and...
Luna, the leading provider of in-home physical therapy, has teamed up with UCI Health, to expand access to patient care by providing...
bottom of page
Comments